LYNNFIELD, Mass.--(BUSINESS WIRE)--Agilis Biotherapeutics, Inc. (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), announced today that Markus Peters, Ph.D., Agilis Chief Commercial Officer (CCO), will give a presentation on the topic “Evaluating Potential Pricing Strategies for Gene Therapies” and participate in the panel discussion “Pricing, Reimbursement & Market Access Considerations” during the 2nd Annual Gene Therapy for Rare Disorders Summit in Boston, MA.
Dr. Peters will discuss opportunities and strategies surrounding pricing and reimbursement in the fast-changing gene therapy space, both for the US and overseas. He will then be joined by other senior industry leaders in a panel discussion on how healthcare systems globally can adapt to the expected entry of an increasing number of innovative treatments with potentially transforming medical benefit.
“All stakeholders -- the biopharmaceutical industry, payers, health technology associations, healthcare providers, patient associations, lawmakers and the finance industry -- need to continue to collaborate to ensure optimal outcomes for patients with rare disorders and advance a sustainable engine for the development and commercialization of innovative treatments,” said Dr. Peters. “As one of the few companies on the threshold of an anticipated registration and commercial launch of an innovative gene therapy, Agilis has been building capabilities to address issues relating to market access, pricing, payment and reimbursement of advanced therapeutics. Being part of shaping the future is especially important for fast-growing new biotech leaders like Agilis that are spearheading innovation.”
The Gene Therapy for Rare Disorders Summit brings together pioneers from the biopharmaceutical and finance industries as well as academia with the goal to discuss new developments in drug development, manufacturing, regulatory and commercialization strategy. This second Annual Meeting takes place in Boston from 30 April to 2 May 2018.
About Agilis Biotherapeutics, Inc.
Agilis is advancing innovative gene therapies designed to provide long-term efficacy for patients with debilitating, often fatal, rare genetic diseases that affect the central nervous system. Agilis’ gene therapies are engineered to impart sustainable clinical benefits by inducing persistent expression of a therapeutic gene through precise targeting and restoration of lost gene function to achieve long-term efficacy. Agilis’ rare disease programs are focused on gene therapy for AADC deficiency, for which the company preparing regulatory filings in the US and EU, Friedreich ataxia and Angelman syndrome, rare genetic diseases that include neurological deficits and result in physically debilitating conditions.
We invite you to visit our website at www.agilisbio.com.
Safe Harbor Statement
Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.
